Program
telitacicept
Also written as “Telitacicept”, “RC18 160mg” and “RC18 240mg”.
Its studies are mostly in Lupus Erythematosus, Systemic · Glomerulonephritis, IGA · Myasthenia Gravis · Sjogren's Syndrome · Lymphoma, Follicular, led by 3 companies.
Drug pageTelitacicept: every studyAll 54 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| RemeGen | 194 open or running | phase 3since Jan 8, 2017 | Aug 24, 2016 | Dec 31, 2026phase 3 · NCT07249632 |
| Vor Biopharmaits history only | 42 open or running | phase 3since Mar 23, 2022 | Mar 23, 2022 | Mar 2027phase 3 · NCT06456580 |
| Innovent Biologicsits history only | 22 open or running | phase 2since Sep 13, 2026 | Sep 13, 2026 | Jan 31, 2027phase 1 · NCT07886476 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of RemeGen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 5 earlier studies, Aug 24, 2016 to Jul 18, 2019.
- Dec 9, 2018Named telitaciceptINNProposed as its International Nonproprietary Name in WHO's List 120
- Sep 1, 2019Phase 3 study in Lupus Erythematosus, SystemicNCT04082416 · 335 enrolled · China
- Jan 6, 2020Phase 1 study in HealthyNCT04235933 · 36 enrolled · China
- Feb 27, 2020Phase 2 study in Glomerulonephritis, IGANCT04291781 · 44 enrolled · China
- Mar 6, 2020Phase 2 study in Systemic Myasthenia GravisNCT04302103 · 29 enrolled · China
- Nov 6, 2020Phase 2 study in Multiple Sclerosis, Relapsing-RemittingNCT04625153 · 8 enrolled · China
- May 21, 2021Phase 2 study in Glomerulonephritis, IGANCT04905212 · 15 enrolled · United States
- Jan 26, 2022Phase 1 study in Lupus Erythematosus, SystemicNCT05247203 · 92 enrolled · China
- Dec 26, 2022Phase 2 study in Lupus NephritisNCT05680480 · 120 planned · China
- Dec 29, 2022Phase 3 study in Primary Sjogren's SyndromeNCT05673993 · 381 enrolled · China
- Jan 8, 2023Phase 1 study in Lupus Erythematosus, SystemicNCT05687526 · 16 enrolled · China
- Feb 12, 2023Phase 3 study in Myasthenia GravisNCT05737160 · 114 enrolled · China
- Mar 5, 2023Phase 3 study in Glomerulonephritis, IGANCT05799287 · 318 enrolled · China
- Nov 18, 2025Phase 3 study in Myasthenia GravisNCT07249632 · 120 planned · China
- Mar 9, 2026Phase 3 study in CTD-ILDNCT07495033 · 260 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Myasthenia GravisNCT07249632
- May 31, 2029Primary completion: phase 3 study in CTD-ILDNCT07495033
TargetBeta
“A fusion protein composed of the extracellular domain of human tumor necrosis factor receptor superfamily member 13B (TNFRSF13B; transmembrane activator and calcium modulator and cyclophilin ligand interactor; TACI) ”NCIt, by rule
Other programs on TNFRSF13B
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| povetaciceptrule | Vertex Pharmaceuticals | phase 3 | 9 |
| SHR-2173 | Jiangsu HengRui Medicine | phase 2 | 8 |
Studies
All 19 RemeGen leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07495033CTD-ILD · China | 3 | Not yet recruiting | May 31, 2029 | 260 |
| NCT07249632Myasthenia Gravis · China | 3 | Recruiting | Dec 31, 2026 | 120 |
| NCT05799287Glomerulonephritis, IGA · China | 3 | Active, not recruiting | Jun 2026 | 318 |
| NCT05737160Myasthenia Gravis · China | 3 | Completed | Nov 26, 2024 | 114 |
| NCT05687526Lupus Erythematosus, Systemic · China | 1 | Completed | Nov 14, 2025 | 16 |
| NCT05673993Primary Sjogren's Syndrome · China | 3 | Completed | Oct 29, 2024 | 381 |
| NCT05680480Lupus Nephritis · China | 2 | Recruiting | Dec 2025 | 120 |
| NCT05247203Lupus Erythematosus, Systemic · China | 1 | Completed | Oct 25, 2023 | 92 |
| NCT04905212Glomerulonephritis, IGA · United States | 2 | Terminated | Nov 9, 2023 | 15 |
| NCT04625153Multiple Sclerosis, Relapsing-Remitting · China | 2 | Terminated | Apr 3, 2026 | 8 |
| NCT04302103Systemic Myasthenia Gravis · China | 2 | Completed | Jan 14, 2022 | 29 |
| NCT04291781Glomerulonephritis, IGA · China | 2 | Completed | May 20, 2021 | 44 |
| NCT04235933Healthy · China | 1 | Completed | Dec 20, 2019 | 36 |
| NCT04082416Lupus Erythematosus, Systemic · China | 3 | Completed | Apr 24, 2022 | 335 |
| NCT04078386Primary Sjögren's Syndrome · China | 2 | Completed | Jun 23, 2021 | 42 |
| NCT03330418Neuromyelitis Optica · China | 3 | Terminated | Apr 3, 2026 | 178 |
| NCT03016013Lymphoma, Follicular · China | 3 | Completed | Nov 19, 2022 | 479 |
| NCT02885610Lupus Erythematosus, Systemic · China | 2 | Completed | Jun 11, 2019 | 249 |
| NCT02882087Lymphoma, Follicular · China | 2 | Terminated | Feb 25, 2019 | 60 |
How it is read
Names in the registry
- “Telitacicept”, 11 entries
- “RC18 160mg”, 3 entries
- “RC18 240mg”, 3 entries
- “RC18 240 mg”, 2 entries
- “RC18 160 mg”, 2 entries
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 6 studies
- Glomerulonephritis, IGA, 4 studies
- Myasthenia Gravis, 4 studies
- Sjogren's Syndrome, 3 studies
- Lymphoma, Follicular, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.